Expanding the Role for Metastasectomy in Advanced-Stage Melanoma

Historically, stage 4 melanoma was considered incurable. In these cases, metastasectomy was performed for only as a palliative measure. But with recent advancements in systemic therapy, metastasectomy has emerged as an effective tool for extending the period of disease control and enhancing overall treatment response. Dana-Farber Brigham Cancer Center is at the forefront of this transformation.

Charles H. Yoon, MD, PhD, FACS, is the director of surgery for cutaneous oncology and melanoma at Dana-Farber Brigham Cancer Center, the cancer center of Dana-Farber Cancer Institute and Brigham and Women’s Hospital. He notes that prior to 2016, stage 4 melanoma had a five-year survival rate of less than 5% and average survival of 13 months. The advent of immunotherapy and targeted therapy has since improved the prognosis, thus expanding the role for surgery.

According to Dr. Yoon, most patients with stage 4 melanoma who receive systemic therapy will have a partial response — the therapy will treat some but not all sites of metastatic disease.

“In that setting, you can carefully select patients who seem to be responding fairly well but have a few sites that remain persistent or enlarging but are surgically resectable,” he says. “By operating and removing the therapy-resistant sites in these patients, we have been able to extend the period of overall response to the systemic therapy. In essence, surgery has become an important adjunct to therapy, and we’re beginning to see more success with it.”

A Regional Leader in Metastasectomy for Melanoma

Dr. Yoon says that Dana-Farber Brigham Cancer Center annually sees over 100 patients with melanoma who are candidates for metastasectomy — one of the largest volumes in the Northeast. Given the center’s extensive experience with these patients, Dr. Yoon and Elizabeth J. Lilley, MD, MPH, then a surgical resident at the Brigham, decided to conduct a retrospective chart review study examining the efficacy of metastasectomy for melanoma.

Using a tissue bank database, Drs. Yoon and Lilley identified patients with stage 3 or 4 melanoma who received preoperative systemic treatment along with metastasectomy between 2010 and 2019. They categorized surgical intent as curative (resection of all metastatic disease), resection of isolated progression or palliative (for symptom relief).

Because immunotherapy and targeted therapy emerged in 2016 — and have been used regularly only since 2018 — the number of patients in the defined population was relatively small: Drs. Yoon and Lilley identified a total of 87 patients who underwent 127 procedures after immunotherapy (95%), targeted therapy (17%) or chemotherapy (22%).

The pair shared study details in a poster presentation at the Society for Surgical Oncology’s 2020 International Conference on Surgical Cancer Care. Among the key findings, overall survival after metastasectomy was 67% at one year and 38% at five years.

“Our review showed that combining surgery in advanced metastatic disease with systemic therapy seems to work fairly well in a population that previously had no options,” Dr. Yoon says. “The dataset is very small, and long-term studies and data on long-term outcomes are not yet available. But given the rapid advances for treatment of metastatic melanoma, there is great optimism for this approach.”

Buying More Time for Patients With Advanced-Stage Melanoma

Dr. Yoon and his colleagues at Dana-Farber Brigham Cancer Center continue to explore new ways to optimize the benefits of metastasectomy for melanoma. One area of focus is conducting selective surgery for generation of tumor vaccine or immune cells.

“Each tumor has its own population of tumor-infiltrating lymphocytes,” he explains. “We’re about to start the process of removing the tumors to study what’s working and not working. We also want to figure out how to manipulate those tumor-infiltrating lymphocytes to make them more effective when we reintroduce them back into the patient at some later time.”

For the time being, Dr. Yoon wants to get the message out that metastasectomy should be a consideration for many patients with advanced-stage melanoma.

“Surgery is clearly becoming more of an option for patients who in the past were deemed inoperable or for whom surgery did not seem to be a good idea prior to the advent of immunotherapy,” he says. “Through a combinatorial approach — using system therapy with surgery — we’re able to buy more time for these patients.”

Study Reveals How Cancer Cells Hijack Mitochondria From Immune Cells

Left: Field emission scanning electron microscopy (FESEM) image shows the formation of a nanotube between a breast cancer cell and an immune cell. Right: Confocal microscopy image shows mitochondria (labeled with green fluorescence dye) traveling from a T cell to a cancer cell through the intercellular nanotube. DNA in the mitochondria was labeled with blue dye.

By taking the brakes off the immune system and allowing it to attack cancer cells, checkpoint inhibitors have spurred significant advances in the treatment of many people with cancer over the past decade. But for patients who do not respond to these drugs — still the majority of people with cancer — alternative interventions are needed.

A team of investigators from Brigham and Women’s Hospital and MIT is using the power of nanotechnology to develop an entirely new approach for boosting the immune response to cancer. Through the use of field-emission scanning electron microscopy (FESEM), they have learned that cancer cells actually steal mitochondria from T cells — an action that both strengthens the cancer cells and weakens the immune response.

“Nanotechnology is helping us to better understand important basic biological functions,” says Shiladitya Sengupta, MS, PhD, co-director of the Brigham’s Center for Engineered Therapeutics and the study’s senior author. “If we could develop a drug to inhibit this hijacking of mitochondria, it could make immune checkpoint therapy much more effective. That’s what we’re now trying to do.”

Dr. Sengupta and team’s latest study was published in November in Nature Biotechnology.

Observing the Transfer of Mitochondria

To study the interactions between cancer cells and immune cells, Dr. Sengupta’s team co-cultured breast cancer cells with different types of immune cells, including T cells. When they looked at the cells using FESEM, they saw that tube-like filaments were connecting the two types of cells. “The cancer cell sends out these nanotubes, which are almost like tentacles,” he says.

When researchers zoomed in further, they noticed there were small particles along the length of these filaments. Suspecting the particles were mitochondria, they labeled these organelles with a fluorescent green dye that bonds to mitochondrial proteins. They then were able to observe the mitochondria being pulled out of the T cells, traveling the length of the nanotubes and being incorporated into the cancer cells.

Further analysis of the metabolic functions of both the immune cells and the cancer cells confirmed that the shift in mitochondria from one cell to the other was affecting cell function.

Look for Drug Strategies to Protect Immune Response

Next, the researchers tested whether they could intervene and prevent the cancer cells from hijacking mitochondria. In mouse models of breast cancer, they injected a drug that blocks the formation of these filaments. When they combined this agent with immune checkpoint inhibitors, they saw a significant reduction in tumor growth in the mice.

Dr. Sengupta’s team is now working with other investigators to develop next-generation filament-inhibiting agents that are more drug-like and potentially could be developed for evaluation in clinical trials.

“The implication of this work is that if we can prevent the mitochondrial hijacking from happening, essentially preventing the T cell’s batteries from being stolen by the cancer cells, then the immune cell retains the energy to attack the cancer cell,” he explains.

Dr. Sengupta expects this approach could be successful for a number of different solid tumors. “We’ve observed this behavior in lung cancer, breast cancer, melanoma and many other tumor types,” he says. “We believe this could be part of a broad strategy for making immunotherapy more effective.”

Brigham and Women’s Hospital is committed to fueling life-saving advancements in cancer research and care. Learn about the Cancer Research Center at the BWH Brigham Research Institute.

Cost-Effectiveness of Surgery for Spinal Metastases Depends on Patient Population Characteristics

Andrew J. Schoenfeld, MD, orthopedic surgeon at Brigham and Women’s Hospital, Elena Losina, PhD, co-director of the Brigham’s OrACORe, and colleagues conducted the first cost-effectiveness analysis of surgery for spinal metastases that accounts for ambulatory function at presentation.


Trial Evaluates Novel Blood Test for Immediate Ovarian Cancer Risk

young woman getting blood drawn

Investigators at Brigham and Women’s Hospital have a clinical trial underway to evaluate the utility and efficacy of a novel blood test that screens women for ovarian cancer risk. Led by Kevin Elias, MD, of the Department of Obstetrics and Gynecology, the trial aims to enroll 500 women who are estimated to be at increased risk of developing the disease due to a family history of cancer or a known mutation in BRCA1, BRCA2 or another gene linked to ovarian cancer.

Read More

Approach Targets Macrophages in BRCA-Linked Breast Cancer

close up of cells
A cyclic immunofluorescence image of triple-negative breast cancer tissue. Shown are tumor cells (Keratin, white), macrophages (CD163, green; CD68, cyan), T cells (red) and nuclei (blue).

PARP inhibitors have become an important part of the arsenal for treating cancers caused by BRCA mutations — including breast cancer. Recently, clinical trials have begun looking at the combination of PARP inhibitors and immune checkpoint inhibitors in breast cancer, with the goal of making treatment more effective and longer lasting.

Read More

Studying New Approaches for Immunotherapy in Renal Cancer

illustration of organ

Immunotherapy with checkpoint inhibitor drugs is an emerging treatment for renal cell carcinoma. Now investigators from Brigham and Women’s Hospital have reported the results from lab research looking at a potential new way to boost the immune system’s ability to fight cancer.

Read More

Preventing Cancer-Associated Thrombosis

Blood clot in the superior vena cava
Blood clot in the superior vena cava associated with a central venous catheter in a 32-year-old woman with Lynch syndrome and advanced colon cancer.

Today’s cancer therapies are helping patients live longer. However, treatments including surgery, radiation, chemotherapy and certain targeted and immunological therapies increase the risk of developing cancer-associated thrombosis (CAT). Physicians at Brigham and Women’s Hospital’s Heart & Vascular Center are working with colleagues at Dana-Farber Cancer Institute (DFCI) to help prevent CAT and minimize its effect on timely cancer care.

Read More

Taking Tumor Boards to the Next Level

Tumor board meeting

While traditional tumor boards are common at most academic medical centers, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has taken its 10-year-old tumor board to the next level by integrating molecular pathology into their discussions.

Read More

Using Nanoparticles to Target Renal Cell Carcinoma

nanoparticlesTargeted therapy has had much less success in treating renal cell carcinoma than in treating many other kinds of cancer. Physician-scientists at Brigham and Women’s Hospital are working on several innovative approaches to address this shortfall.

Read More

Neoadjuvant Immunotherapy for Head & Neck Cancer Patients

Neoadjuvant Immunotherapy
Image of tumor sample from a patient who demonstrated pathologic response to neoadjuvant pembrolizumab (10X magnification, courtesy of Dr. Rebecca Chernock)

Researchers at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) are advancing innovative approaches to decrease tumor recurrence rates in patients with HPV-negative squamous cell carcinoma of the head and neck (SCCHN).

Read More